Answers are grounded in this paper and cite their sources.
Observational analysis shows 5-year overall survival at 90.9% in locally advanced rectal cancer patients, indicating effectiveness of neoadjuvant chemoradiotherapy.
The goal of this study was to look at the long-term survival outcomes and clinical characteristics of stage II/III locally advanced rectal cancer (LARC) patients who acquired pathological complete response (pCR) following neoadjuvant chemoradiotherapy (NCRT). The clinicopathological characteristics and treatment details of 277 LARC patients with pCR, relapse-free survival (RFS), overall survival (OS), and locoregional and systemic recurrence rates, were assessed. The 5-year RFS and OS rates were 85.6% and 90.9%. The rates of local and systemic recurrence were 3.6% and 7.9%. Our study confirmed the favorable results in survival in patients with LARC who achieved pCR.
No takes yet. Share an insight, caveat, or question.
Uysal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: